The relationship between impulsivity and methamphetamine use severity in a community sample

Moallem, Nathasha R.; Courtney, Kelly E.; Ray, Lara A.

doi:10.1016/j.drugalcdep.2018.01.034

Cited by 24 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Psychostimulant addicts show high levels of both behavioral and decisional impulsivity than do healthy controls (20–27). It is hypothesized that this impulsive behavior is responsible for high rates of relapse among these addicts during abstinence.…”

Section: Drug-induced Cognitive Deficitsmentioning

confidence: 99%

Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits

D’Souza

2019

Front. Psychiatry

View full text Add to dashboard Cite

Addiction to psychostimulants like cocaine, methamphetamine, and nicotine poses a continuing medical and social challenge both in the United States and all over the world. Despite a desire to quit drug use, return to drug use after a period of abstinence is a common problem among individuals dependent on psychostimulants. Recovery for psychostimulant drug-dependent individuals is particularly challenging because psychostimulant drugs induce significant changes in brain regions associated with cognitive functions leading to cognitive deficits. These cognitive deficits include impairments in learning/memory, poor decision making, and impaired control of behavioral output. Importantly, these drug-induced cognitive deficits often impact adherence to addiction treatment programs and predispose abstinent addicts to drug use relapse. Additionally, these cognitive deficits impact effective social and professional rehabilitation of abstinent addicts. The goal of this paper is to review neural substrates based on animal studies that could be pharmacologically targeted to reverse psychostimulant-induced cognitive deficits such as impulsivity and impairment in learning and memory. Further, the review will discuss neural substrates that could be used to facilitate extinction learning and thus reduce emotional and behavioral responses to drug-associated cues. Moreover, the review will discuss some non-pharmacological approaches that could be used either alone or in combination with pharmacological compounds to treat the above-mentioned cognitive deficits. Psychostimulant addiction treatment, which includes treatment for cognitive deficits, will help promote abstinence and allow for better rehabilitation and integration of abstinent individuals into society.

show abstract

Section: Drug-induced Cognitive Deficitsmentioning

confidence: 99%

Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits

D’Souza

2019

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…After 5 consecutive days of administration, the difference between the administration and control group decreased (Moallem et al, 2018). After high dose, high frequency, or long time administration, the energy reserve may be depleted (Moallem et al, 2018). The patients in this study were basically deprived from METH for about 2 months.…”

Section: Discussionmentioning

confidence: 73%

“…An increase in energy metabolism was found in the serum of amphetamine-administered rats. After 5 consecutive days of administration, the difference between the administration and control group decreased ( Moallem et al, 2018 ). After high dose, high frequency, or long time administration, the energy reserve may be depleted ( Moallem et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies on methamphetamine addicted animals found that abnormal energy metabolism was the biochemical basis of toxicity and addiction ( Cservenka and Ray, 2017 ; Moallem et al, 2018 ). An increase in energy metabolism was found in the serum of amphetamine-administered rats.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, amphetamines cause serum/plasma neurotransmitter disturbances mainly in the glutamate-glutamine-GABA system ( Moallem et al, 2018 ). Glutamate-Glutamine disturbance was observed both in withdrawal animals and in the WMA patients ( Shima et al, 2011 ; Chen et al, 2015 ; Su et al, 2018 ), and this disturbance may be related to a continuous search for drugs and the high relapse risk ( Zheng et al, 2014 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Potential Regulatory Network of Glutamate Metabolic Pathway Disturbance in Chinese Han Withdrawal Methamphetamine Abusers

Peng

Chen

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

ObjectsTo explore the long-term influence of methamphetamine abuse on metabolomics character, with gas chromatography-mass spectrometry (GS-MS) technology, and the potential regulatory network using the bioinformatics method.MethodsForty withdrawal methamphetamine abusers (WMA) were recruited from Shanghai Gaojing Forced Isolation Detoxification Institute. Forty healthy controls (HC) were recruited from society. GS-MS technology was used to detect metabolic products in serum. A bioinformatics method was used to build a regulatory network. Q-PCR was used to detect the candidate gene expressions, and ELISA was used to detect the regulatory enzyme expressions.ResultsFour pathways were significantly changed in the MA compared to the HC: (1) the arginine synthesis pathway, (2) alanine, aspartic acid and glutamate metabolic pathway, (3) cysteine and methionine metabolic pathway, and (4) the ascorbate and aldarate pathway (enrichment analysis p < 0.05, Impactor factor > 0.2). When focusing on the ‘Alanine, aspartate, and glutamate metabolism’ pathway, a regulatory network was established, and the expression of candidate regulatory genes and enzymes was verified. It was found that the expression of DLG2 (Discs large MAGUK scaffold protein 2), PLA2G4 (Phospholipase A2 group IVE), PDE4D (Phosphodiesterase 4D), PDE4B (Phosphodiesterase 4B), and EPHB2 (Ephrin type-B receptor 2) were significantly different between the two groups (p < 0.05), However, after adjusting for age and BMI, only DLG2, PLA2G4, and EPHB2 remained significant (p < 0.05). The expression of enzymes was not significantly different (p > 0.05).ConclusionMethamphetamine abuse influences the metabolic process in the long term, and DLG2, PLA2G4, and EPHB2 may regulate the glutamate metabolism pathway.

show abstract

Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder

2020

View full text Add to dashboard Cite

In the wake of the opioid crisis, methamphetamine has reemerged as a challenge to mental health clinicians and researchers alike. Methamphetamine is now available in different forms such as ice, powder, and pills, with different pharmacokinetic characteristics that make them popular among certain types of individuals. 1 Recent seizure data suggest that methamphetamine production and trafficking are spreading into new areas of the globe. 2 According to the Automation of Reports and Consolidated Orders System, methamphetamine consumption increased 4-fold between 2015 and 2016 and total stimulant use doubled in the last decade. 3 From 2011 through 2016, the age-adjusted rate of drug overdose deaths involving methamphetamine more than tripled. 4 Moreover, drug overdose deaths involving cocaine, amphetamines, or both substances combined increased 42.4% from 12 122 in 2015 to 17 258 in 2016. 5 Based on the most recent data from the National Survey on Drug Use and Health, 6 the 12-month prevalence of individuals aged 12 years or older reporting methamphetamine use has increased by 195% from its low in 2010 to 2018 (Figure 1), and it is estimated that 1.86 million Americans used methamphetamine in 2018. These numbers underline the importance of paying attention to the possibility of the next substance use crisis. However, whereas opioid use disorder can be treated pharmacologically 7 and behaviorally, 8 there are significant challenges for the treatment of methamphetamine use disorder (MUD). This review focuses on 3 specific aspects of MUD. First, the neurobiology of methamphetamine is more complex than the traditional view of it as a monoaminergic modulator. Second, the clinical presentation is not limited to the symptoms associated with use disorder but extend to medical presentations, most notably the cardiovascular and cerebrovascular systems. Third, pharmacologic interventions focused on modulating the monoaminergic pathways have largely failed, and new pharmacologic approaches are necessary to focus on novel treatment targets. In the final section, several suggestions will be proposed for both clinicians and researchers to advance the understanding of MUD. Biological Pathways, Neural Basis, and CognitionMethamphetamine has been conceptualized primarily as a releaser of dopamine, serotonin, noradrenaline, and adrenaline from nerve terminals in the central and peripheral nervous system, 9 which occurs via several different mechanisms, including (1) redistributing catecholamines from synaptic vesicles to the cytosol, (2) reversing the plasma membrane transport of neurotransmitters, (3) blocking the activity of monoamine transporters, (4) decreasing the expression of dopamine transporters at the cell surface, (5) inhibiting monoamine oxidase activity, and (6) increasing the activity and IMPORTANCE The prevalence of and mortality associated with methamphetamine use has doubled during the past 10 years. There is evidence suggesting that methamphetamine use disorder could be the next substance use crisis in the United ...

show abstract

The relationship between impulsivity and methamphetamine use severity in a community sample

Abstract: The current findings extend previous research by providing additional evidence that MA use is associated with increased self-reported impulsivity and highlights the importance of evaluating impulsivity as a multidimensional construct.

Cited by 24 publications

References 47 publications

Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits

Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits

The Potential Regulatory Network of Glutamate Metabolic Pathway Disturbance in Chinese Han Withdrawal Methamphetamine Abusers

Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder

Contact Info

Product

Resources

About